Research brings big-government services Made in treating leukemia, the Past Decade Lymphoma (HealthDay)
HealthDay Reporter Amanda Gardner
Reporter Wed Nov – 24 11: 47 pm ET healthday
WEDNESDAY, November 24, HealthDay News)--made significant advances in treating Clinical blood cancers at an early stage with the bone marrow and blood stem cells of human origin in recent years, treatment-related complications and death risk to reduce considerably the present level of a new study shows.
the 1990s, and 2007 was 41% reduction in between, in the event of death in the analysis of more than 2 500 patients in the Fred Hutchinson Cancer Center in Seattle, blood cancers-the market leader in the field and other malignancies are dealt with in General may present a risk to public health.
Fred Hutchinson Cancer Center, researchers who carry out research, stated that the treatment of complications such as infection and dramatic decreases in body injury.
A study was published in the New England Journal of Medicine Nov 24 problem
"We've made a huge increase in a position to understand the very complex procedure and have produced spectacular results," said study author Dr. George top McDonald, gastroenterologist with Hutchinson and medicine at the University of Washington in Seattle, Professor at the University of Copenhagen. "This is one of the most complex procedures in medicine and we realize that we are not a lot of prior complications."
Dr. Mitchell Smith, head of the lymphoma service Fox Chase Cancer Center in Philadelphia, a positive general trend of increasing the numbers of out-of-the-box-unless the exact--can extrapolate other care takes the Center.
"The things that they made the most of it is generally accepted in most units, even if you do not need elinpankkien be careful, for they shall select the patient population, and they are the experts," he said. "Smaller centers that you do not do as many procedures may obtain exactly the same results, but the trend is clearly better."
High-risk material blood cancers at an early stage of leukemia, lymphoma and myeloma treatment had revolutionized Allogeneic bone marrow transplantation of blood or put at the disposal of the 1970s.
This advance before blood cancers at an early stage of patients had a lot of only options. High dose chemotherapy or radiation treatments designed to kill the cancer of the blood (which share faster than regular cells) often damaged or destroyed in the bone marrow of the patient, while leaving it to the oxygen concentration, may be submitted to the necessary blood cells to combat infection and stop the bleeding. Transplanting bone marrow stem cells from the donor to a patient's healthy,--if all went well--the power to submit these returned its critical blood cells.
Although therapy, met with great success, it was also the serious side effects, including infections, body injury and graft-versus-host disease (GVHD), which were serious, older and frailer patients to prevent the running procedure much.
But over the last 40 years has seen much improvement in the management of these problems.
The authors of the Study, which compared to 1,418 patients undergoing their first Allogeneic blood Hutchinson at 1,148 for the years 1993 to 1997, which were the patients ten years later, in 2007 the same procedure in the context of the experience.
Patients had leukemia, lymphoma, multiple myeloma and myelodysplastic syndrome and got a peripheral blood stem cells or bone marrow unrelated donors. Add peripheral blood stem cell transplantations were carried out in a subsequent period, and the bone marrow of the transplantations were carried out less.
In the event of the death without Relapse products decreased by 52% and without relapse, in General, at the beginning of the number of death (200 days post procedure) declined by 60%.
Approximately 55% of the transplantations running patients survived a year earlier period, at a later date during the period, compared to 70%.
And was only about a problem, although the rates of improvements to the 2003-2007 is treated patients were older and sicker than they are treated in 10 years earlier. For example, the opportunities for developing serious Graft-versus-host disease fell from 67% of the Decade, in part thanks to better drugs. There was also less disease caused by infections and fewer treatment-related damage, liver, kidneys and lungs, analysis was found.
The authors cannot be sure of the reasons for the improvements, but speculate is to make the more controlled chemotherapy doses; less toxic ' stabilisation ' attack lymphocytes; removing the body better detection and viral, bacterial and fungal preventive, as well as better antifungal (and other) as well as donors and lifestyle, as well as the availability of better correspond to the recipients.
Peripheral blood stem cells, which increased the time interval, it is also easier to use, the patient, they argued.
In addition, Smith drug Gleevec patients with chronic myeloid keep leukaemia patients as a result of the introduction of these must be removed from the need for organ transplantation, was added.
"I think we all feel comfortable that we are doing much better than me, you were doing 10 years ago, in particular at the beginning of the terms of the deaths and to prevent and manage the toxicity and it ran out of much of this group have become [Fred Hutchinson Cancer Center]," said Smith. "They are those who lead the way."
Dr. Nelson Chao, transplantation program, and medicine at Duke University in Durham, N.C., Professor agree that "a lot of these treatments are now standard in many places."
McDonald and five other factors indicated that ties to the pharmaceutical companies. The study was financed by the US National institutes of Health.
For more information about the
Leukemia & Lymphoma Society is more stem cells in the area of organ transplantation.
Comments
Post a Comment